Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Genetic variants in the <i>GRIN</i> genes that encode N-methyl-D-aspartate receptor (NMDAR) subunits have been identified in various neurodevelopmental disorders, including epilepsy. We identified a <i>GRIN1</i> variant from an individual with early-onset epileptic encephalopathy, evaluated functional changes to NMDAR properties caused by the variant, and screened FDA-approved therapeutic compounds as potential treatments for the patient. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Whole exome sequencing identified a missense variant in <i>GRIN1</i>. Electrophysiological recordings were made from <i>Xenopus</i> oocytes and transfected HEK cells to determine the NMDAR biophysical properties as well as the sensitivity to agonists and FDA-approved drugs that inhibit NMDARs. A beta-lactamase reporter assay in transfected HEK cells evaluated the effects of the variant on the NMDAR surface expression. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>A recurrent de novo missense variant in <i>GRIN1</i> (c.1923G>A, p.Met641Ile), which encodes the GluN1 subunit, was identified in a pediatric patient with drug-resistant seizures and early-onset epileptic encephalopathy. In vitro analysis indicates that GluN1-M641I containing NMDARs showed enhanced agonist potency and reduced Mg<sup>2+</sup> block, which may be associated with the patient's phenotype. Results from screening FDA-approved drugs suggested that GluN1-M641I containing NMDARs are more sensitive to the NMDAR channel blockers memantine, ketamine, and dextromethorphan compared to the wild-type receptors. The addition of memantine to the seizure treatment regimen significantly reduced the patient's seizure burden. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Interpretation</h3><p>Our finding contributes to the understanding of the phenotype–genotype correlations of patients with <i>GRIN1</i> gene variants, provides a molecular mechanism underlying the actions of this variant, and explores therapeutic strategies for treating <i>GRIN1</i>-related neurological conditions. </p></section>

Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology

GRIN1 variants associated with neurodevelopmental disorders reveal channel gating pathomechanisms

Heterogeneous Clinical and Functional Features of GRIN2D-related Developmental and Epileptic Encephalopathy.

Clinical and Therapeutic Significance of Genetic Variation in the GRIN Gene Family Encoding NMDARs

De Novo Mutations and Rare Variants Occurring in NMDA Receptors.

De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor

Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors

[Neurodevelopmental disorders associated with variants of GRIN gene family].

Differential functional consequences of GRIN2A mutations associated with schizophrenia and neurodevelopmental disorders

Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties

Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy

GRIN2B disease-associated mutations disrupt the function of BK channels and NMDA receptor signalling nanodomains

Complex Functional Phenotypes of NMDA Receptor Disease Variants

De novo GRIN2A variants associated with epilepsy and autism and literature review

Characterization of Mice Carrying a Neurodevelopmental Disease-Associated GluN2B(L825V) Variant

Molecular Insights into the Role of Pathogenic Nssnps in GRIN2B Gene Provoking Neurodevelopmental Disorders

Clinical and functional consequences of GRIA variants in patients with neurological diseases

Pathophysiology and Disease Models

N-terminal alternative splicing of GluN1 regulates the maturation of excitatory synapses and seizure susceptibility.

GRIN2A Variants Associated with Idiopathic Generalized Epilepsies.

Distances from ligands as main predictive features for pathogenicity and functional effect of variants in NMDA receptors